Q3 2026
Released Nov 3, 2026, before the open
10-Q filed Nov 3, 2026, 37 days after period end · 0000078003-26-000127
What the release said
On November 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2026.
Pfizer reported third-quarter 2026 revenues of $16.6 billion, relatively flat year-over-year operationally, with reported diluted EPS of $0.56 and Adjusted diluted EPS of $0.87.¶2
Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion, and raised and narrowed Adjusted diluted EPS guidance to $2.95 to $3.05.¶2¶3¶4
The 2026 Adjusted diluted EPS guidance includes a one-time $650 million Acquired In-Process R&D charge tied to the Innovent Biologics, Inc. in-licensing and collaboration agreement, with an unfavorable impact of approximately $0.10.¶5
Pfizer returned $7.3 billion of cash dividends, or $1.29 per share, in the first nine months of 2026, and has completed no share repurchases to date in 2026.¶6¶7
Third-quarter Eliquis revenues rose $513 million, or 25%, operationally, while Paxlovid revenues fell $771 million, or 63%, operationally.¶8¶9
- Third-quarter 2026 revenues
- $16.6 Billion¶2
- Third-quarter 2026 Reported diluted EPS
- $0.56¶2
- Third-quarter 2026 Adjusted diluted EPS
- $0.87 Third-Quarter 2026; same as the prior-year quarter¶2
- Full-year 2026 revenue guidance
- $62.0 to $64.0 billion Raised by $1.5 billion at the midpoint, from $60.5 to $62.5 billion previously¶3
- Full-year 2026 Adjusted diluted EPS guidance
- $2.95 to $3.05 Raised and narrowed from $2.80 to $3.00 previously¶4
- Innovent in-licensing charge
- $650 million One-time Acquired In-Process R&D charge recorded in the third quarter of 2026¶5
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $16.58B | $16.65B | $17.70B | $13.49B |
| Net Income | $3.24B | $3.54B | $4.47B | -$2.38B |
| EPS Diluted | $0.56 | $0.62 | $0.78 | -$0.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR